Physician profile
Ellen L Singleton
NPI 1891027249
$847.44
in general payments reported to CMS, 2019-2025
15 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $397 · 2022: $143 · 2023: $56.07 · 2024: $98.34 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $307.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $304.10 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $145.54 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $91.78 | 2022-2023 | Rexulti |
| Glaxosmithkline, LLC. | $50.48 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $45.65 | 2021-2024 | Airsupra |
| Novartis Pharmaceuticals Corporation | $43.11 | 2022-2025 | |
| Exact Sciences Corporation | $28.89 | 2025 | Cologuard Collection Kit |
| Pfizer INC. | $23.17 | 2021 | |
| Lilly USA, LLC | $19.28 | 2025 | Mounjaro, Zepbound |
| Atland Pharmaceuticals, LLC | $19.25 | 2024 | Orphenadrine Citrate, Aspirin and Caffeine, Tolmetin Sodium |
| Janssen Pharmaceuticals, INC | $19.16 | 2025 | Spravato |
| Ibsa Pharma INC. | $16.68 | 2025 | Tirosint, Licart, Flector |
| Dexcom, INC. | $14.29 | 2024 | Dexcom G6 Transmitter |
| Hologic Sales and Service, LLC | $13.14 | 2021 | |
| Xeris Pharmaceuticals, INC. | $12.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Singleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.